Asenapine: A review of acute and extension phase data in bipolar disorder

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 645-648

  Mcintyre, Roger S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Acute mania; Asenapine; Bipolar disorder; Maintenance

Indexed keywords

ASENAPINE; OLANZAPINE; PLACEBO;

AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR MANIA; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSGEUSIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPESTHESIA; MANIA; MIXED MANIA AND DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT INDICATION; WEIGHT GAIN;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SEROTONIN;

EID: 79959978210     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00200.x     Document Type: Review

References (11)

1. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):28-36.
2. Tohen M, Zarate CA, Jr., Hennen J, et al. The McLean-Harvard First-Episode Mania Study: Prediction of recovery and first recurrence. Am J Psychiatry 2003;160:2099-2107.
3. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: Primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry 2006;163:217-224.
4. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009;11:225-255.
5. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73.
6. Tarazi FI, Shahid M. Asenapine maleate: A new drug for the treatment of schizophrenia and bipolar mania. Drugs Today (Barc) 2009;45:865-876.
7. McIntyre RS. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev Neurother 2010;10:645-649.
8. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11:673-686.
9. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: A double-blind extension study. Bipolar Disord 2009;11:815-826.
10. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. J Affect Disord 2010;122:27-38.
11. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE, Jr. Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-516.